Track-1: Biomarkers in Translational Medicine
Translational medicine is the emerging discipline involving the translation of laboratory findings into the design and implementation of early-stage clinical trials. TM focuses on translating pre-clinical data from in vivo, in vitro, and in silicon research into the clinic to help design trials, determine methods and choose the biomarkers. Biomarkers play a vital role in the development and growth of translational medicine. Predictive biomarkers are the markers which can be used to identify subpopulations of patients who are most likely to respond to a given therapy. Biomarkers in clinical drug development enable continued clinical development of drugs suspected of human irrelevant animal toxicities– ensuring patient safety, reducing drug failures and loss of time. A genomic biomarker is a measurable DNA or RNA characteristic that is an indicator of normal biologic processes, pathogenic processes and response to therapeutic or other interventions. Specific and sensitive mRNA biomarkers are used for the identification of skin in ‘touch DNA’ evidence.
Track-2: Role of Translational Research in Blood Disorders
People may be affected by many different types of blood conditions and blood cancers. Common blood disorders include anemia, Clotting and bleeding disorders such as hemophilia blood clots, and blood cancers such as leukemia, lymphoma, and myeloma. Clinical studies emphasize the paradox that both anaemia and transfusion are associated with organ injury and increased morbidity and mortality across a wide span of disease states and surgical interventions Among the other blood disorders. Leukemia is the most common form of cancer in children, affecting about 3,000 children each year in the United States, accounting for about 30 percent of childhood cancers. Functional and translational genomic approaches will be used to investigate mechanisms of globin gene regulation and proteomics to study the red blood cell membrane function in health and disease. A blood and marrow transplant replaces a person’s abnormal stem cells with healthy ones from another person (a donor). This procedure allows the recipient to get new stem cells that work properly.
Track-3: Translational Cardiology and Vascular Medicine
The goal of the Cardiac Translational Research is to accelerate translation of promising new fundamental research discoveries for the treatment of heart failure and arrhythmias through well-designed clinical trials that demonstrate efficacy and safety. Vascular medicine encompasses many different disease states. As the field of vascular medicine evolves, the scope of diseases being treated changes. Cardiac remodeling refers to the changes in size, shape, structure and physiology of the heart after injury to the myocardium. The injury is typically due to acute myocardial infarction. To characterize the increase in lipoprotein translation by hypothyroidism, adipocytes were prepared from control and hypothyroid rats. Whereas LPL synthesis was higher in hypothyroid adipocytes, with no change in mRNA levels, there was no increase in hormone-sensitive lipase (HSL) synthesis. To determine whether a transacting translation regulatory factor was present, a cytoplasmic fraction was prepared from control and hypothyroid adipocytes, and added to an in vitro translation system containing the hLPL mRNA. Clinical outcomes with non-biologic theraphy, given early in the course of the disease, are as good as with biologic therapies. Combinations of treatments are usually required to achieve rapid and sustained remission.
Track-4: Translational Therapeutics and Technologies
As Project moves from the research phase into the development, true technology transfer needs to take place. Therapeutic angiogenesis is an experimental area of treatment of ischemia, the condition which associated with decrease in blood supply to certain body organs. Hepatocellular carcinoma (HCC) is a common solid cancer and the third most frequent cause of cancer-related mortality worldwide Molecular targeted therapies are used for treating HCC. Recent advances of biological drugs have broadened the scope of therapeutic targets for a variety of human diseases. This holds true for dozens of RNA-based therapeutics currently under clinical investigation for diseases ranging from genetic disorders to HIV infection to various cancers. Proteomics has the ability to interrogate a variety of biospecimens for their protein contents and accurately measure the concentrations of these proteins. Deciphering DNA sequences is essential for virtually all branches of biological research.
Track-5: Translational Modeling of Efficacy and Safety
Animal and Translational Models for CNS Drug Discovery combines the experience of academic, clinical and pharmaceutical neuroscientists in a unique collaborative approach to provide a greater understanding of the relevance of animal models of neuropsychiatric disorders and t